BioAge Labs, a clinical-stage biotechnology company, maps human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. A core focus area is muscle aging, which causes loss of strength, mobility and function; drives multiple age-related diseases; and decreases overall quality of life.
Analysis of our proprietary longitudinal human aging datasets has identified apelin signaling as an attractive therapeutic target for muscle aging. Higher apelin signaling is strongly predictive of improved muscle function, reduced frailty and overall longevity. This webinar will present a detailed review of BGE-105—an agonist of the apelin receptor APJ— from initial target identification through preclinical validation and clinical development. BGE-105 development will target acute muscle atrophy and chronic muscle loss, and improve healthspan.